From StockNews.com: Johnson & Johnson (NYSE:JNJ) early Tuesday posted mixed fourth quarter results, offered a tepid outlook, and said it would look to sell its diabetes treatment units.
In a sign that a deal could be close to being struck, healthcare products giant Johnson & Johnson (NYSE:JNJ) has reportedly upped its takeover offer for European biotech giant Actelion.
Health care giant Johnson & Johnson (NYSE:JNJ) early today posted better-than-expected third quarter earnings results and lifted its full-year guidance.
Another quarter and another superb performance from pharmaceutical giant Johnson & Johnson (NYSE:JNJ). For the most part, healthcare ETFs have been performing in-line with the markets. Investors looking to avoid volatility tend to gravitate toward the big pharma plays.